MLHC.. preliminary 2nd quarter results next week Back

New Post Public Reply Private Reply Replies (0) Message Board
PennyHick PennyHick #21513
MLHC.. preliminary 2nd quarter results next week

Back to Full Listing on OTCQB
TUSTIN, Calif., Jan. 17, 2014 /PRNewswire/ -- M Line Holdings, Inc. (OTCQB: MLHC) ("M Line"), a provider of products and services to the precision high tech segment of both the aerospace and medical industries as well as seller of high end pre-owned Japanese Computer Numerically Controlled ("CNC") Equipment, today announced that it is now current with all its filings and is now listed back on the OTCQB.

(Logo:  http://photos.prnewswire.com/prnh/20140113/LA44709LOGO)

Bruce Barren, CEO of M Line, stated, "Our financial statements now meet the quality required by our new auditors, MaloneBailey, and are now positioned to reflect further evidence of our positive turnaround when we announce [b]preliminary 2nd quarter results next week.[/b]"

Tony Anish, M Line's COO, stated, "We are pleased that we will be filing Q2 results prior to the scheduled deadlines".
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

AST SpaceMobile: Analyzing Growth Amid Market Fluctuations

Updated Category News Views 151

Market Movement and AST SpaceMobile's Growth Potential AST SpaceMobile Inc (NASDAQ: ASTS) has recently experienced a period of consolidation following a remarkable rally that saw its stock increase by triple digits in under three months. For investors monitoring the daily fluctuations in AST SpaceMobile’s stock chart, this pullback may trigger concerns. However, the...

Continue Reading
Foghorn Therapeutics: Future Directions and Financial Health

Updated Category News Views 92

Foghorn Therapeutics: Future Directions and Financial Health Foghorn Therapeutics Inc. (NASDAQ: FHTX) is embarking on an exciting journey in the field of oncology, focusing on groundbreaking therapies that seamlessly integrate with the body’s chromatin regulatory mechanisms. Among these is FHD-909, a pioneering oral selective SMARCA2 inhibitor. This focus highlights the...

Continue Reading
Essen Health Achieves Top Savings Rate in 2024

Updated Category News Views 11

Leading the Pack with Impressive Savings When it comes to healthcare innovation and cost efficiency, Essen Health Care's Atlas IPA is firing on all cylinders. In the cutthroat world of healthcare savings, where every penny counts, they’ve managed to crank out a 21% net savings rate. This isn’t just a small-town record, folks. We're talking about leading the nation...

Continue Reading
Alps Group Completes Merger with Globalink Investment and Expands

Updated Category News Views 242

Alps Group's Landmark Merger with Globalink Investment Inc. Alps Group Inc, the parent company of Alps Life Sciences Inc., recently celebrated the closing of its business combination with Globalink Investment Inc. This merger marks a significant milestone in the biotechnology landscape, showcasing Alps Group's commitment to advancing healthcare solutions. The Journey to...

Continue Reading
Morien Resources Secures Funding for Future Development Goals

Updated Category News Views 75

Morien Resources Corp. Secures Financing Morien Resources Corp. is thrilled to announce the successful closing of a significant non-brokered Listed Issuer Financing Exemption offering, known as the LIFE Offering. The company has raised gross proceeds of $1,600,000, allowing it to issue 8,888,889 common shares at a price of $0.18 each. This injection of capital is pivotal...

Continue Reading